{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:16:46Z","timestamp":1791170206362,"version":"4.1.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1097\/cad.0b013e3282f2d8e4","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T04:46:52Z","timestamp":1236228412000},"page":"209-216","source":"Crossref","is-referenced-by-count":82,"title":["Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals"],"prefix":"10.1097","volume":"19","author":[{"given":"Jie","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Fettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert L.","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Riek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Rakhit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210203","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0022-3565(24)35162-6","article-title":"Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358\u2009744: dynamics of receptor inhibition in situ and antitumor effects in athymic mice","volume":"291","author":"Pollack","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"R2-13-20210203","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/01.cad.0000127664.66472.60","article-title":"Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models","volume":"15","author":"Higgins","year":"2004","journal-title":"Anticancer Drugs"},{"key":"R3-13-20210203","first-page":"777","article-title":"Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma","volume":"1","author":"Ng","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"R4-13-20210203","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"P\u00e9rez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"R5-13-20210203","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Souli\u00e8res","year":"2004","journal-title":"J Clin Oncol"},{"key":"R6-13-20210203","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2005.02.477","article-title":"Phase I\/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1\/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"R7-13-20210203","first-page":"77","article-title":"Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).","volume":"121","author":"Moore","year":"2005","journal-title":"Proc ASCO Gastrointest Cancers Symp"},{"key":"R8-13-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"R9-13-20210203","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"R11-13-20210203","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1124\/dmd.105.007765","article-title":"Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers","volume":"34","author":"Ling","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R12-13-20210203","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/0091270005284193","article-title":"Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects","volume":"46","author":"Frohna","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R13-13-20210203","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.clpt.2006.04.007","article-title":"Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer","volume":"80","author":"Lu","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R14-13-20210203","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003088-199936030-00004","article-title":"Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications","volume":"36","author":"Fleisher","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"R15-13-20210203","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1146\/annurev.nu.16.070196.002123","article-title":"Effects of food on drug absorption","volume":"16","author":"Welling","year":"1996","journal-title":"Annu Rev Nutr"},{"key":"R16-13-20210203","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2165\/00003088-200443150-00005","article-title":"Effects of food on the clinical pharmacokinetics of anticancer agents","volume":"43","author":"Singh","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R17-13-20210203","doi-asserted-by":"crossref","DOI":"10.1201\/9781420036091","article-title":"Design and analysis of cross-over trials","author":"Jones","year":"2003"},{"key":"R18-13-20210203","article-title":"Design and analysis of bioavailability and bioequivalence studies","author":"Chow","year":"2000"},{"key":"R19-13-20210203","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacological study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J Clin Oncol"},{"key":"R20-13-20210203","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/bdd.2510140904","article-title":"The effect of food on the relative bioavailability of fadrozole hydrochloride","volume":"14","author":"Choi","year":"1993","journal-title":"Biopharm Drug Dispos"},{"key":"R21-13-20210203","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/(SICI)1099-081X(199708)18:6<489::AID-BDD36>3.0.CO;2-P","article-title":"Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5\u2009mg single oral administration","volume":"18","author":"Sioufi","year":"1997","journal-title":"Biopharm Drug Dispos"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0b013e3282f2d8e4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T01:09:14Z","timestamp":1738976954000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-200802000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e3282f2d8e4","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}